

# Christopher James Sampson BA (Hons), MSc, PhD

[0000-0001-9470-2369](tel:0000-0001-9470-2369)

Principal Economist

Office of Health Economics, 7th floor Southside, 105 Victoria Street, London SW1E 6QT

Email: [csampson@ohe.org](mailto:csampson@ohe.org); Tel: +44 (0)20 7747 8866

[www.chrissampson.me](http://www.chrissampson.me)

## Areas of expertise

- Economic evaluation
- Clinical trials
- Decision modelling
- Health-related quality of life measurement
- Mental health

## Employment

2019-present Principal Economist, Office of Health Economics, London

2017-2019 Senior Economist, Office of Health Economics, London

2013-2017 Research Assistant, School of Medicine, University of Nottingham

2010-2013 Research Assistant, School of Sociology & Social Policy, University of Nottingham

## Other positions

2021-present Associate Editor, *Frontiers in Health Services*

2021-present Chair, ISPOR Open Source Models Special Interest Group

2019-present Webmaster, Health Economists' Study Group

2016-present Editorial Board member, *PharmacoEconomics – Open*

2011-present Editor-in-Chief and founder, *The Academic Health Economists' Blog*

2019-2021 Honorary Project Health Economist, Oxford University Hospitals NHS Foundation Trust

## Qualifications

2011-2020 PhD, University of Nottingham

*Optimising the cost-effectiveness of risk-based screening for diabetic retinopathy*

2009-2010 MSc Economics & Health Economics, University of Sheffield

2006-2009 BA Economics, University of Sheffield

## Awards

2017 Andrew Hendry Postgraduate Scholarship, University of Nottingham

2012 Best Young Researcher, East Midlands & South Yorkshire MHRN

## Memberships

American Economic Association – AEA; Health Economists' Study Group – HESG; Health Technology Assessment International – HTAi; International Health Economics Association – iHEA; International Society for Pharmacoeconomics and Outcomes Research – ISPOR; Royal Economic Society

## Teaching

2014-2017 Professional Practice for the Clinical Scientist in the NHS, Medical Physics and Clinical Engineering, University of Liverpool

2015-2017 Core Training, Centre for Doctoral Training in Rehabilitation and Healthcare Research, University of Nottingham  
2015 Health Economics and Management, MBS (Health Executive), Keele University  
2012-2013 Health Economics, Doctoral Training Centre, University of Nottingham

## Refereeing

### *Journals*

Aphasiology; Applied Health Economics and Health Policy; BMC Psychiatry; BMJ Open; British Food Journal; British Journal of General Practice; British Journal of Occupational Therapy; British Journal of Psychiatry; Clinical Rehabilitation; Clinical Therapeutics; Criminal Behaviour and Mental Health; Diabetic Medicine; Epidemiology and Psychiatric Sciences; European Journal of Health Economics; Evidence-Based Mental Health; Gates Open Research; Health and Quality of Life Outcomes; Health Services and Delivery Research; Health Technology Assessment; International Journal of Law and Psychiatry; Journal of Affective Disorders; Journal of Health Economics; Journal of Mental Health; Medical Decision Making: Policy & Practice; PharmacoEconomics; PharmacoEconomics - Open; PLOS ONE; Psychological Medicine; Quality of Life Research; Value in Health [Full details available on [Publons](#)]

### *Funding bodies*

Medical Research Council, National Institute for Health Research (NIHR) – Efficacy and Mechanism Evaluation Programme; NIHR – Health Services and Delivery Research; NIHR – Health Technology Assessment, NIHR – Public Health Research; Research Grants Council (Hong Kong)

### *Conferences*

HESG meetings (as discussant); EuroQol Early Career Researchers Meeting (as discussant); iHEA Congress; ISPOR Europe; ISPOR International; UK Stroke Forum

## Grants awarded

### *2021*

- Conceptualising bolt-ons: identifying key questions. *EuroQol Research Foundation*. €42,840. [PI]

### *2020*

- Development and testing of EQ-5D-5L bolt-on descriptors for hearing. *EuroQol Research Foundation*. €149,130. [PI]

### *2019*

- Health state utility rescaling and interpersonal comparisons. *EuroQol Research Foundation*. €12,200. [Co-I]
- What aspects of quality of life are important to people with experience of cognitive or visual impairment? A qualitative investigation. *EuroQol Research Foundation*. €14,800. [Co-I]

### *2018*

- Development and psychometric testing of EQ-5D-5L bolt-on descriptors for vision and cognition: A study in the UK and Australia. *EuroQol Research Foundation*. €118,785. [PI]
- SMaRteN: Student Mental Health Research Network. *UK Research and Innovation*. £1,095,606. [Co-I]
- Drop dead: an assessment of the conceptual basis for 'death' as an anchor in health state valuation. *EuroQol Research Foundation*. €12,500. [Co-I]

## Publications

### Journal articles

2021

- **Sampson, C.J.** (2021) NICE and the EQ-5D-5L: ten years trouble. *Pharmacoeconomics – Open*. DOI: [10.1007/s41669-021-00315-1](https://doi.org/10.1007/s41669-021-00315-1)
- **Sampson, C.J.**, Bell, E., Cole, A., Miller, C.B., Marriott, T., Williams, M., Rose, J. (2021) Digital cognitive behavioural therapy for insomnia and primary care costs in England: an interrupted time series analysis. *BJGP Open*. DOI: [10.3399/BJGPO.2021.0146](https://doi.org/10.3399/BJGPO.2021.0146)
- **Sampson, C.J.**, Firth, I., and Towse, A. (2021) Health opportunity costs and expert elicitation: a comment on Soares et al. *Medical Decision Making*. DOI: [10.1177/0272989X20987211](https://doi.org/10.1177/0272989X20987211)
- **Sampson, C.J.**, Zhang, K., Parkin, D., and Hampson, G. (2021) Exclusive human milk diet for very preterm babies in England: protocol for a cost-effectiveness and budget impact analysis. *F1000 Research* 10:21. DOI: [10.12688/f1000research.22450.1](https://doi.org/10.12688/f1000research.22450.1)

2019

- **Sampson, C.J.**, Arnold, R., Bryan, S., Clarke, P., Ekins, S., Hatswell, A., Hawkins, N., Langham, S., Marshall, D., Sadatsafavi, M., Sullivan, W., Wilson, E.C.F., and Wrightson, T. (2019) Transparency in decision modelling: what, why, who and how? *Pharmacoeconomics*. 37,1355-1369. DOI: [10.1007/s40273-019-00819-z](https://doi.org/10.1007/s40273-019-00819-z)
- Broadbent, D., **Sampson, C.J.**, Wang, A., Howard, L., Williams, A., Howlin, S., Appelbe, D., Moitt, T., Cheyne, C., Rahni, M., Kelly, J., Collins, J., García-Fiñana, M., Stratton, I., James, M., and Harding, S. (2019) Individualised Screening for Diabetic Retinopathy: the ISDR study. Rationale, design and methodology for a randomised controlled trial comparing annual and personalised variable-interval risk-based screening. *BMJ Open*. 9(e025788). DOI: [10.1136/bmjopen-2018-025788](https://doi.org/10.1136/bmjopen-2018-025788)

2017

- **Sampson, C.J.** and Wrightson, T. (2017) Model registration: a call to action. *Pharmacoeconomics – Open* 1(2), 73-77. DOI: [10.1007/s41669-017-0019-2](https://doi.org/10.1007/s41669-017-0019-2)

2016

- **Sampson, C.J.**, James, M., Broadbent, D. and Harding, S.P. (2016) Stratifying the NHS Diabetic Eye Screening Programme: into the unknown? *Diabetic Medicine* 33(12), 1612-1614. DOI: [10.1111/dme.13192](https://doi.org/10.1111/dme.13192)
- Malins, S., Kai, J., Atha, C., Avery, A., Guo, B., James, M., Patel, S., **Sampson, C.**, Stubble, M and Morriss, R. (2016) Cognitive Behaviour Therapy for Long-term Frequent Attenders in Primary Care: A Feasibility Case Series and Treatment Development Study. *British Journal of General Practice* 66(651), e729-e736. DOI: [10.3399/bjgp16X686569](https://doi.org/10.3399/bjgp16X686569)
- Morriss, R., Garland, A., Nixon, N., Guo, B., James, M., Kaylor-Hughes, C., Moore, R., Ramana, R., **Sampson, C.**, Sweeney, T., Dalgleish, T. and the NIHR CLAHRC Specialist Mood Disorder Study Group. (2016) Efficacy and cost-effectiveness of a specialist depression service versus usual specialist mental health care to manage persistent depression: a randomised controlled trial. *The Lancet Psychiatry* 3(9), 821-831. DOI: [10.1016/S2215-0366\(16\)30143-2](https://doi.org/10.1016/S2215-0366(16)30143-2)
- Sayal, K., Taylor, J.A., Valentine, A., Guo, B., **Sampson, C.J.**, Sellman, E., James, M., Hollis, C. and Daley, D. (2016) Effectiveness and cost-effectiveness of a brief school-based group programme for parents of children at risk of ADHD: a cluster randomised controlled trial. *Child: Care, Health and Development* 42(4), 521-533. DOI: [10.1111/cch.12349](https://doi.org/10.1111/cch.12349)
- Roberts, A., Wales, J., Smith, H., **Sampson, C.J.**, Jones, P. and James, M. (2016) A randomised controlled trial of laser scanning and casting for the construction of ankle

foot orthoses. *Prosthetics and Orthotics International* 40(2), 253-261. DOI: [10.1177/0309364614550263](https://doi.org/10.1177/0309364614550263)

2015

- Morriss, R., Patel, S., Kai, J., Atha, C., Avery, A., Guo, B., James, M., Malins, S., **Sampson, C.** and Stubley, M. (2015) Clinical characteristics of persistent frequent attenders in primary care: case control study. *Family Practice* 32(6), 624-630. DOI: [10.1093/fampra/cmz076](https://doi.org/10.1093/fampra/cmz076)
- **Sampson, C.J.**, Tosh, J.C., Cheyne, C.P., Broadbent, D. and James, M. (2015) Health state utility values for diabetic retinopathy: protocol for a systematic review and meta-analysis. *Systematic Reviews* 4:15. DOI: [10.1186/s13643-015-0006-6](https://doi.org/10.1186/s13643-015-0006-6)

2014

- **Sampson, C.J.**, James, M., Whitehead, P. and Drummond, A.E.R. (2014) An introduction to economic evaluation in occupational therapy: cost-effectiveness of pre-discharge home visits after stroke (HOVIS). *British Journal of Occupational Therapy* 77(7), 330-335. DOI: [10.4276/030802214X14044755581664](https://doi.org/10.4276/030802214X14044755581664)

2013

- **Sampson, C.J.**, James, M., Huband, N., Geelan, S. and McMurran, M. (2013) Cost implications of treatment non-completion in a forensic personality disorder service. *Criminal Behaviour and Mental Health* 23(5), 321-335. DOI: [10.1002/cbm.1866](https://doi.org/10.1002/cbm.1866)
- **Sampson, C.J.**, Whitehurst, D.G.T. and Street, A. (2013) Do patients registered with CAM-trained GPs really use fewer health care resources and live longer? A response to Kooreman and Baars. *Eur J Health Econ* (2012). 13:469-776. *The European Journal of Health Economics* 14(4), 703-705. DOI: [10.1007/s10198-013-0466-3](https://doi.org/10.1007/s10198-013-0466-3)
- Drummond, A.E.R., Whitehead, P., Fellows, K., Sprigg, N., **Sampson, C.J.**, Edwards, C. and Lincoln, N.B. (2013) Occupational therapy pre-discharge home visits for patients with a stroke (HOVIS): results of a feasibility randomized controlled trial. *Clinical Rehabilitation* 27(5), 387-397. DOI: [10.1177/0269215512462145](https://doi.org/10.1177/0269215512462145)
- **Sampson, C.J.** (2013) Generic preference based measures: how economists measure health benefit. *Advances in Clinical Neuroscience and Rehabilitation* 13(5), 23-24.

2012

- Sayal, K., Daley, D., James, M., Yang, M., Batty, M.J., Taylor, J.A., Pass, S., **Sampson, C.J.**, Sellman, E., Valentine, A. and Hollis, C. (2012) Protocol Evaluating the effectiveness of a school-based group programme for parents of children at risk of ADHD: the "PARENTS, TEACHERS AND CHILDREN WORKING TOGETHER (PATCHWORK)" cluster RCT protocol. *BMJ Open* 2(5), 1-8. DOI: [10.1136/bmjopen-2012-001783](https://doi.org/10.1136/bmjopen-2012-001783)

#### Book chapters

- **Sampson, C.J.**, Neri, M., and Zhang, K. (2020) Use of pharmacoeconomics in drug reimbursement: what can we learn from international experience? In R.J.G. Arnold (Eds.) *Pharmacoeconomics: From Theory to Practice* (pp. 241-253). CRC Press. DOI: [10.1201/9780429491368-14](https://doi.org/10.1201/9780429491368-14)
- **Sampson, C.J.** (2016) Identifying objects of value at the end of life. In J. Round (Eds.) *Care at the End of Life: An Economic Perspective* (pp. 103-122). Springer International Publishing. DOI: [10.1007/978-3-319-28267-1\\_8](https://doi.org/10.1007/978-3-319-28267-1_8)

#### Working papers, preprints, and reports

- Bell, E., Pan, J., and **Sampson, C.** (2021) Economics analyses of interventions for student mental health: protocol for a systematic review. *MedRxiv*. DOI: [10.1101/2021.11.09.21255793](https://doi.org/10.1101/2021.11.09.21255793)
- **Sampson, C.**, Parkin, D., and Devlin, N. (2020) Drop Dead: Is Anchoring at 'Dead' a Theoretical Requirement in Health State Valuation? *OHE Research Paper*, London: The Office of Health Economics.
- **Sampson, C.** and Garau, M. (2019) How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy. *OHE Briefing*, London: The Office of Health Economics.

- **Sampson, C.**, O'Neill, P., and Lorgelly, P. (2018) The Impact of New Medicines in the NHS: 70 Years of Innovation. *OHE Consulting Report*, London: The Office of Health Economics.
- Berdud, M., Garau, M., Neri, M., O'Neill, P., **Sampson, C.**, and Towse, A. (2018) R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C. *OHE Research Paper*, London: The Office of Health Economics.
- Cole, A., O'Neill, P., **Sampson, C.**, and Lorgelly, P. (2018) Barriers to Uptake of Minimal Access Surgery in the United Kingdom. *OHE Consulting Report*, London: The Office of Health Economics.
- Canaway, A.G., **Sampson, C.J.** (2016) Long term economic evaluation of interventions targeting multiple mental health conditions: protocol for a rapid review of methods. *PeerJ Preprints* 4:e1988v1. DOI: [10.7287/peerj.preprints.1988v1](https://doi.org/10.7287/peerj.preprints.1988v1)
- **Sampson, C.J.**, James, M. and Whynes, D. (2013) The relationship between individual risk and cost-effectiveness in screening interventions.

### Online articles

I have written many articles and blog posts for a variety of websites including The Academic Health Economists' Blog, The National Elf Service, OHE News, The LSE Impact Blog, The Conversation, and The Institute of Mental Health.

### **Conference papers and presentations**

#### 2021

- Supply-side cost-effectiveness thresholds: questions for evidence-based policy // 19th-23rd June // HTAi Annual Meeting
- Supply-side cost-effectiveness thresholds: one name, many faces? (poster) // 19th-23rd June // HTAi Annual Meeting
- Drop Dead: is it time to remove 'dead' from health state valuation? (Issue Panel) // 20th May // ISPOR Virtual Conference
- Sleepio: real-world evaluation and NICE assessment of a digital health technology // 21st April // Network of Alberta Health Economists Rounds

#### 2020

- Open source models in HEOR: benefits, challenges, and ISPOR members' perceptions // 24th September // ISPOR Educational Webinar
- Candidate bolt-ons for cognition and vision: qualitative findings from a development programme // 23rd September // EuroQol Descriptive System Working Group Virtual Meeting
- Paradigm shifts in health state valuation - what is the future of utilities for QALYs? (Issue Panel) // 20th May // ISPOR Virtual Conference
- Development and qualitative testing of EQ-5D-5L bolt-ons for cognition and vision // 1st March // EuroQol Early Career Researcher meeting, Prague, Czech Republic
- Risk calculation engines, cost-effectiveness analysis, and Microsoft Excel: lessons from an intractable model // 8th January // Health Economists' Study Group, Newcastle University, Newcastle, UK
- The impact of a digital sleep-improvement program on health care costs // 7th January // Health Economists' Study Group, Newcastle University, Newcastle, UK

#### 2019

- Development of EQ-5D-5L bolt-ons for cognition and vision // 5th November // ISPOR Europe, Copenhagen, Denmark
- The impact of a digital sleep-improvement program on health care costs // 5th November // ISPOR Europe, Copenhagen, Denmark
- Drop dead: is anchoring at 'dead' a theoretical requirement in health state valuation? // 8th January // Health Economists' Study Group, University of York, York, UK

#### 2018

- Drop dead: is anchoring at 'dead' a theoretical requirement in health state valuation? // 21st September // 35th EuroQol Group Scientific Plenary, Lisbon, Portugal
- Optimising risk-based screening: the case of diabetic eye disease // 3rd June // Health Technology Assessment International, Vancouver, Canada
- Long-term evaluation of broad mental health interventions: a review // 3rd June // Health Technology Assessment International, Vancouver, Canada
- Building bridges not walls: can we develop sustainable and sharable cost-effectiveness models? // 4th June // Health Technology Assessment International, Vancouver, Canada

#### 2017

- Putting the 'extra' in animal welfare: health maximisation for non-human animals // 27th March // International Society for Economics and Social Sciences of Animal Health Inaugural Meeting, Aviemore, UK
- Systematic review and meta-analysis of health state utility values for diabetic retinopathy: implications for model-based economic evaluation // 4th January // Health Economists' Study Group, University of Birmingham, Birmingham, UK

#### 2016

- Risk-based screening for diabetic retinopathy: a model for individualisation // 8th September // Third EuHEA PhD Student-Supervisor and Early Career Researcher Conference, Universitat Internacional de Catalunya, Barcelona, Spain
- Microcosting diabetic eye screening: estimation of personal expense, attendance and health care resource use // 24th June // European Association for the Study of Diabetes Eye Complications Study Group: 26th Annual Meeting, Manchester, UK
- Health-related quality of life of people attending screening for diabetic retinopathy within a trial setting // 24th June // European Association for the Study of Diabetes Eye Complications Study Group: 26th Annual Meeting, Manchester, UK
- Individualised cost-effectiveness analysis in risk-based screening: practical and ethical? // 6th January // Health Economists' Study Group, University of Manchester, Manchester, UK

#### 2015

- Cost-effectiveness of a risk-based screening programme for diabetic retinopathy: a modelling approach // 28th June // EASDec 2015: 25th Annual Meeting, University of Turin, Turin, Italy
- Cost-effectiveness of a specialist depression service for resistant depression // 29th March // 12th Workshop on Costs and Assessment in Psychiatry, International Center of Mental Health Policy and Economics, Venice, Italy
- Individualised cost-effectiveness analysis in risk-based screening: practical and ethical? // 2nd March // Personalised Medicine and Resource Allocation conference, University of Oxford, Oxford, UK

#### 2013

- Subjective well-being and generic preference-based measures of health: an empirical contribution // 10th January // Health Economists' Study Group, University of Exeter, Exeter, UK

#### 2012

- Economic evaluation of occupational therapy pre-discharge home visits for patients with a stroke: issues arising // 10th October // The role of health economics in responding to the research needs of the health service through CLAHRCs, University of Birmingham, Birmingham, UK
- Readiness for treatment in personality disorder // 20th June // Health Services Research Network Symposium, Manchester, UK
- Cost implications of treatment non-completion in personality disorder // 9th March // East Midlands & South Yorkshire MHRN Annual Research Meeting, Nottingham, UK
- Findings from the CLAHRC-NDL project: 'The costs of non-completion in treatment for personality disorder' // 27th January // Engaging People with Personality Difficulties in Services, University of Nottingham, Nottingham, UK

- Optimising cost-effectiveness in risk-based screening programmes: a modelling approach // 12th January // Health Economists' Study Group and Collège des Économistes de la Santé Workshop, Maison Méditerranéenne des Sciences de l'Homme, Aix en Provence, France

*2011*

- Findings from the CLAHRC-NDL project: 'The costs of non-completion in treatment for personality disorder' // 20th May // Personality Difficulties Development Event, Lincolnshire Partnership NHS Foundation Trust, Sleaford, UK
- The cost implications of non-completion: a Markov model // 24th March // British and Irish Group for the Study of Personality Disorder, University of Oxford, Oxford, UK